DOI:
10.1055/s-00000129
Kardiologie up2date
LinksClose Window
References
Koenig W, Ridker PM.
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5 % or Framingham risk > 20 %: post hoc analyses of the JUPITER trial requested by European health authorities.
Eur Heart J 2010; [Epub ahead of print]: -
We do not assume any responsibility for the contents of the web pages of other providers.